Jerry M Keith, 83Olney, MD

7101558, Sep 5, 2006

Jun 26, 2001

10/312272

Tod J. Merkel - Bethesda MD, US
Jerry M. Keith - Olney MD, US
Xiaoming Yang - Rockville MD, US

The United States of America as represented by the Department of Health and Human Services - Washington DC

A61K 39/02
A01N 63/00

4242001, 424 934, 424 932, 4242341

The present invention provides a vaccine production strain of that produces a pertussis toxin in high yield. The present invention provides a method for creating a cell line which produces a toxin comprising the steps of introducing a plasmid containing a DNA encoding antibiotic resistance into a strain, selecting for isolates in which the DNA encoding antibiotic resistance is recombinantly incorporated into the chromosome in place of the toxin gene, introducing a plasmid containing DNA encoding subunits of the toxins into the isolates; and, selecting for isolates in which DNA encoding toxin subunit is recombinantly incorporated into the chromosome, the resulting cells producing the toxin. The present invention further provides a method for creating a cell line which produces a toxin and does not express filamentous hemagglutinin.

2010015, Jun 17, 2010

Aug 14, 2009

12/541804

Mark A. Miller - Chevy Chase MD, US
Rachel Schneerson - Bethesda MD, US
John B. Robbins - New York NY, US
Jerry Keith - Olney MD, US

A61K 39/385
A61P 31/16
C07K 17/06

4241941, 530404

Disclosed are immunogenic conjugates having the general formula:were M2e is the influenza M2 ectodomain (M2e) peptide; Cys is a cysteine amino acid residue present in the M2e peptide; S the sulfur present in the cysteine amino acid residue; CH2-CO—NH—CH2-CH2-CO the linking group; NH the amine group present in a lysine residue of the carrier; Lys is a lysine amino acid residue and Pr the carrier protein. Also disclosed are isolated immunogens that include an immunogenic fragment of an influenza HA protein including the polybasic cleavage site, wherein the immunogenic fragment of the influenza HA protein has been modified to remove an N-terminal leader amino acid sequence and a C-terminal transmembrane domain. Also disclosed are methods producing an influenza vaccine specific for an identified influenza strain.

2011018, Jul 28, 2011

Oct 1, 2009

13/121574

Rachel Schneerson - Bethesda MD, US
John B. Robbins - New York NY, US
Fathy Majadly - Frederick MD, US
Christopher P. Mocca - Columbia MD, US
Jerry Keith - Olney MD, US
Louis Miller - Cabin John MD, US
Ruth Nussenzweig - New York NY, US
Darrell T. Liu - Bethesda MD, US

A61K 39/015
C07K 14/445
G01N 33/566
A61P 37/04
A61P 33/06

4241931, 530405, 436501

Disclosed are immunogenic conjugates which elicit an immune response to proteins. In particular examples, the proteins include sexual stage surface proteins, circumsporozoite protein (CSP), or immunogenic portions of CSP. Also provided herein are immunogenic compositions including one or more of the disclosed immunogenic conjugates and a pharmaceutically acceptable carrier. Further provided is a method of eliciting an immune response to in a subject, comprising administering to the subject an immunogenic composition disclosed herein.

2013021, Aug 22, 2013

Apr 25, 2013

13/870547

The United States of America, as represented by the Secretary, Department of Health and Human Services - , US
New York University - , US
John B. Robbins - New York NY, US
Fathy Majadly - Frederick MD, US
Christopher P. Mocca - Columbia MD, US
Jerry Keith - Olney MD, US
Louis Miller - Cabin John MD, US
Ruth Nussenzweig - New York NY, US
Darrell T. Liu - Bethesda MD, US

New York University - New York NY
Services - Bethesda MD

C07K 14/00

4241931, 530363, 530367, 530350

Disclosed are immunogenic conjugates which elicit an immune response to proteins. In particular examples, the proteins include sexual stage surface proteins, circumsporozoite protein (CSP), or immunogenic portions of CSP. Also provided herein are immunogenic compositions including one or more of the disclosed immunogenic conjugates and a pharmaceutically acceptable carrier. Further provided is a method of eliciting an immune response to in a subject, comprising administering to the subject an immunogenic composition disclosed herein.

2014023, Aug 21, 2014

Sep 28, 2012

14/348321

- Bethesda MD, US
Jerry Keith - Olney MD, US
Rachel Schneerson - Bethesda MD, US

The United States of America, as represented by the Secretary, Dept.of Health and Human Services - Bethesda MD

A61K 47/48

4241861, 530363, 42419611

Disclosed are immunogenic conjugates having the general formula: HA2-XXX-Pr, where HA2 is the influenza HA2 fusion peptide or a portion thereof, XXX is a linker and Pr is the carrier. Methods of producing an immune response in a subject using the disclosed immunogenic conjugates, as well as methods of treating, ameliorating or preventing influenza infection, are also disclosed.

2014020, Jul 24, 2014

Jan 16, 2014

14/157417

- Rockville MD, US
Rachel Schneerson - Bethesda MD, US
John B. Robbins - New York NY, US
Jerry Keith - Olney MD, US

The United States of America, as represented by the Secretary, Dept. of Health and Human Services - Rockville MD

C07K 17/06

4241861, 530404, 435 693

Disclosed are immunogenic conjugates having the general formula:were M2e is the influenza M2 ectodomain (M2e) peptide; Cys is a cysteine amino acid residue present in the M2e peptide; S the sulfur present in the cysteine amino acid residue; CH2-CO—NH—CH2-CH2-CO the linking group; NH the amine group present in a lysine residue of the carrier; Lys is a lysine amino acid residue and Pr the carrier protein. Also disclosed are isolated immunogens that include an immunogenic fragment of an influenza HA protein including the polybasic cleavage site, wherein the immunogenic fragment of the influenza HA protein has been modified to remove an N-terminal leader amino acid sequence and a C-terminal transmembrane domain. Also disclosed are methods producing an influenza vaccine specific for an identified influenza strain.